Skip to main content

These 13 Nifty stocks rallied 11-72% from last record high to current record high

Only few stocks drove this recovery - major ones were Reliance Industries, TCS and Infosys, which are index heavyweights

The benchmark indices touched a record high in January 2020, but the COVID-led lockdown spoilt the party on the Street. Indices fell 40 percent from the record high levels to hit a low in March.

The market got a boost after the government started the Unlock process in June. The liquidity flow and positive global cues also lifted the sentiment.

Nifty and Sensex have made fresh record highs this week with Sensex scaling the 43,000-mark for the first time. But the upward journey from March to November was not broad-based as only two sectors saw substantial gains.

IT and Pharma looked strong from last record high in January to current record high in November, rising 29 percent and 35 percent, respectively. And the rest are still in the red during same period as of publishing this article.

It meant that only few stocks drove this recovery - major ones were Reliance Industries, TCS and Infosys, which are index heavyweights.

Among the Nifty50 stocks, 13 gained in double digits from last record high to current record high. Divis Laboratories was the biggest gainer with 72 percent rally.

Dr Reddy's Laboratories, Cipla, Infosys, Wipro, HCL Technologies and Reliance Industries rallied 37-53 percent, while JSW Steel, Hero Motocorp, Tata Consultancy Services, Asian Paints, Britannia Industries and HDFC Bank gained 11-23 percent during same period.



On the other hand, 16 stocks from Nifty50 list remained under pressure, falling 10-42 percent during January-November period.

ONGC, Coal India, IndusInd Bank, Bajaj Finserv, GAIL India, Indian Oil Corporation, ITC, State Bank of India, UPL, Tata Motors, NTPC,

Larsen & Toubro, Axis Bank, Bharat Petroleum Corporation, SBI Life Insurance Company and Tata Steel were top 16 losers from last record.

Experts feel the market rally would be broad-based when these above stocks participate in the economic recovery going ahead and now with the improving data points along with government support indicated that these stocks could participated in the up move in Samvat 2077.

"The Indian economy has witnessed a strong acceleration over the past few months led by manufacturing with the PMI reading of 58.9 for October being the highest since mid 2008. Services PMI reading of 54.1 for the month of October is the first reading above 50 since March and points to green shoots of recovery for the services sector. We expect the economic recovery to continue from here on led by continued acceleration in the services sector which should provide support to the markets," Jyoti Roy, DVP- Equity Strategist at Angel Broking told Moneycontrol.

He expects both cyclical and defensive sector will continue to do well. "Going forward we expect the broader markets will do well as compared to the benchmarks and within broader markets cyclical should do well given revival in earnings in FY22," he said.

Source- Moneycontrol.com

Comments

Post a Comment

Popular posts from this blog

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...
Post a Comment
Read more

Brokerages place bets on Titan, see double-digit upside in the stock

Titan can get benefits from the strong market share in the jewellery and wrist watches segment, mainly driven by a wide range of product portfolio catering mainly to the premium and value-added designer jewellery segment. After three consecutive sessions of losses, shares of Titan Company rose over a percent in morning trade on BSE on September 23. The company was dealt a severe blow by COVID-19 as the pandemic triggered strict lockdowns completely battered the retail sector. In the calendar year so far, shares of this one of the largest, most efficient and profitable specialty retailer in India are 7 percent down. The company reported a net standalone loss of Rs 270 crore for the quarter ended June 2020 as the COVID-19 pandemic hit business. The loss was higher than a CNBC-TV18 poll estimate of Rs 175 crore. Standalone revenue during the quarter declined 62.3 percent year-on-year to Rs 1,862 crore compared to the corresponding period last fiscal. Light at the end ...
Post a Comment
Read more

Check Chemcon Speciality Chemicals IPO allotment status in four simple steps

Equity shares will get credited into the accounts of eligible investors by September 30 and the listing of equity shares will be on October 1, 2020. Chemcon Speciality Chemicals, the manufacturer for pharmaceutical and oilfields industries, is expected to announce the basis of allotment early next week. As per the schedule provided by the company, the finalisation of the basis of the allotment will be done by September 28 and the initiation of refunds or unblocking of funds from ASBA account will take place on September 29. Equity shares will get credited to the accounts of eligible investors by September 30 and the listing will be on October The IPO comprised a fresh issue of Rs 165 crore and an offer for sale of Rs 153 crore by promoters. The company will utilise fresh issue proceeds for expansion of manufacturing facility, working capital requirements, and general corporate purposes. Chemcon manufactures specialised chemicals, such as Hexamethyldisilazane (HMDS) and Chloromethyl Iso...
Post a Comment
Read more